{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:19Z","timestamp":1794047419247,"version":"4.8.0"},"reference-count":47,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>\u03b22-glycoprotein I (\u03b22-GPI) is a serum protein widely recognized as the main target of antibodies present in patients with antiphospholipid syndrome (APS). \u03b22-GPI binds to activated endothelial cells, platelets and leukocytes, key players in thrombus formation. We developed a new targeted thrombolytic agent consisting of nanobubbles (NB) coated with recombinant tissue plasminogen activator (rtPA) and a recombinant antibody specific for cell-bound \u03b22-GPI. The therapeutic efficacy of targeted NB was evaluated in vitro, using platelet-rich blood clots, and in vivo in three different animal models: i) thrombosis developed in a rat model of APS; ii) ferric chloride-induced mesenteric thrombosis in rats, and iii) thrombotic microangiopathy in a mouse model of atypical hemolytic uremic syndrome (C3-gain-of-function mice). Targeted NB bound preferentially to platelets and leukocytes within thrombi and to endothelial cells through \u03b22-GPI expressed on activated cells. In vitro, rtPA-targeted NB (rtPA-tNB) induced greater lysis of platelet-rich blood clots than untargeted NB. In a rat model of APS, administration of rtPA-tNB caused rapid dissolution of thrombi and, unlike soluble rtPA that induced transient thrombolysis, prevented new thrombus formation. In a rat model of ferric chloride triggered thrombosis, rtPA-tNB, but not untargeted NB and free rtPA, induced rapid and persistent recanalization of occluded vessels. Finally, treatment of C3-gain-of-function mice with rtPA-tNB, that target \u03b22-GPI deposited in kidney glomeruli, decreased fibrin deposition, and improved urinalysis data with a greater efficiency than untargeted NB. Our findings suggest that targeting cell-bound \u03b22-GPI may represent an efficient and thrombus-specific thrombolytic strategy in both APS-related and APS-unrelated thrombotic conditions.<\/jats:p>","DOI":"10.3324\/haematol.2022.281505","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T15:13:57Z","timestamp":1664464437000},"page":"1861-1872","source":"Crossref","is-referenced-by-count":14,"title":["Plasminogen activator-coated nanobubbles targeting cellbound \u03b22-glycoprotein I as a novel thrombus-specific thrombolytic strategy"],"prefix":"10.3324","volume":"108","author":[{"given":"Paolo","family":"Macor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Durigutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Argenziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Smith-Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Capolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Di Leonardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Marchbank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio Stefano","family":"Tolva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Semeraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta T.","family":"Ammollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Colucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Cavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Meroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Tedesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"49487","doi-asserted-by":"crossref","unstructured":"Meroni PL, Borghi MO, Grossi C, Chighizola CB, Durigutto P, Tedesco F. Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?. Nat Rev Rheumatol. 2018; 14(7):433-440.","DOI":"10.1038\/s41584-018-0032-6"},{"key":"49488","doi-asserted-by":"crossref","unstructured":"Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011; 7(6):330-339.","DOI":"10.1038\/nrrheum.2011.52"},{"key":"49489","doi-asserted-by":"crossref","unstructured":"Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018; 379(13):1290-1291.","DOI":"10.1056\/NEJMc1808253"},{"key":"49490","doi-asserted-by":"crossref","unstructured":"Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. The global anti-phospholipid syndrome score in primary APS. Rheumatology (Oxford). 2015; 54(1):134-138.","DOI":"10.1093\/rheumatology\/keu307"},{"key":"49491","doi-asserted-by":"crossref","unstructured":"Cervera R, Serrano R, Pons-Estel GJ. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015; 74(6):1011-1018.","DOI":"10.1136\/annrheumdis-2013-204838"},{"key":"49492","doi-asserted-by":"crossref","unstructured":"Miyakis S, Lockshin MD, Atsumi T. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2):295-306.","DOI":"10.1111\/j.1538-7836.2006.01753.x"},{"key":"49493","doi-asserted-by":"crossref","unstructured":"de Groot PG, Urbanus RT. The significance of autoantibodies against beta2-glycoprotein I. Blood. 2012; 120(2):266-274.","DOI":"10.1182\/blood-2012-03-378646"},{"key":"49494","doi-asserted-by":"crossref","unstructured":"Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013; 368(11):1033-1044.","DOI":"10.1056\/NEJMra1112830"},{"key":"49495","doi-asserted-by":"crossref","unstructured":"Agostinis C, Biffi S, Garrovo C. In vivo distribution of beta2 glycoprotein I under various pathophysiologic conditions. Blood. 2011; 118(15):4231-4238.","DOI":"10.1182\/blood-2011-01-333617"},{"key":"49496","doi-asserted-by":"crossref","unstructured":"Meroni PL, Macor P, Durigutto P. Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. Blood. 2016; 127(3):365-367.","DOI":"10.1182\/blood-2015-09-672139"},{"key":"49497","doi-asserted-by":"crossref","unstructured":"Agostinis C, Durigutto P, Sblattero D. A non-complementfixing antibody to beta2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood. 2014; 123(22):3478-3487.","DOI":"10.1182\/blood-2013-11-537704"},{"key":"49498","doi-asserted-by":"crossref","unstructured":"Fischetti F, Durigutto P, Pellis V. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood. 2005; 106(7):2340-2346.","DOI":"10.1182\/blood-2005-03-1319"},{"key":"49499","doi-asserted-by":"crossref","unstructured":"Thiebaut AM, Gauberti M, Ali C. The role of plasminogen activators in stroke treatment: fibrinolysis and beyond. Lancet Neurol. 2018; 17(12):1121-1132.","DOI":"10.1016\/S1474-4422(18)30323-5"},{"key":"49500","doi-asserted-by":"crossref","unstructured":"Campbell BC. Thrombolysis and thrombectomy for acute ischemic stroke: strengths and synergies. Semin Thromb Hemost. 2017; 43(2):185-190.","DOI":"10.1055\/s-0036-1585078"},{"key":"49501","doi-asserted-by":"crossref","unstructured":"Rabinstein AA. Update on treatment of acute ischemic stroke. Continuum (Minneap Minn). 2020; 26(2):268-286.","DOI":"10.1212\/CON.0000000000000840"},{"key":"49502","doi-asserted-by":"crossref","unstructured":"Waqas M, Kuo CC, Dossani RH. Mechanical thrombectomy versus intravenous thrombolysis for distal large-vessel occlusion: a systematic review and meta-analysis of observational studies. Neurosurg Focus. 2021; 51(1):e5.","DOI":"10.3171\/2021.4.FOCUS21139"},{"key":"49503","doi-asserted-by":"crossref","unstructured":"Cavalli R, Bisazza A, Trotta M. New chitosan nanobubbles for ultrasound-mediated gene delivery: preparation and in vitro characterization. Int J Nanomedicine. 2012; 7(1):3309-3318.","DOI":"10.2147\/IJN.S30912"},{"key":"49504","doi-asserted-by":"crossref","unstructured":"Durigutto P, Grossi C, Borghi MO. New insight into antiphospholipid syndrome: antibodies to beta2glycoprotein I-domain 5 fail to induce thrombi in rats. Haematologica. 2019; 104(4):819-826.","DOI":"10.3324\/haematol.2018.198119"},{"key":"49505","doi-asserted-by":"crossref","unstructured":"Colucci M, Scopece S, Gelato AV, Dimonte D, Semeraro N. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis - study in healthy subjects and correlation with blood fibrinolytic parameters. Thromb Haemost. 1997; 77(4):725-729.","DOI":"10.1055\/s-0038-1656041"},{"key":"49506","doi-asserted-by":"crossref","unstructured":"Mutch NJ, Moore NR, Mattsson C, Jonasson H, Green AR, Booth NA. The use of the Chandler loop to examine the interaction potential of NXY-059 on the thrombolytic properties of rtPA on human thrombi in vitro. Br J Pharmacol. 2008; 153(1):124-131.","DOI":"10.1038\/sj.bjp.0707543"},{"key":"49507","doi-asserted-by":"crossref","unstructured":"Colucci M, Binetti BM, Tripodi A, Chantarangkul V, Semeraro N. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood. 2004; 103(6):2157-2161.","DOI":"10.1182\/blood-2003-06-2169"},{"key":"49508","doi-asserted-by":"crossref","unstructured":"Li W, Nieman M, Sen Gupta A. Ferric chloride-induced murine thrombosis Models. J Vis Exp. 2016; 115:1-12.","DOI":"10.3791\/54479"},{"key":"49509","doi-asserted-by":"crossref","unstructured":"Dobrina A, Pausa M, Fischetti F. Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo. Blood. 2002; 99(1):185-192.","DOI":"10.1182\/blood.V99.1.185"},{"key":"49510","doi-asserted-by":"crossref","unstructured":"Smith-Jackson K, Yang Y, Denton H. Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice. J Clin Invest. 2019; 129(3):1061-1075.","DOI":"10.1172\/JCI99296"},{"key":"49511","doi-asserted-by":"crossref","unstructured":"Capolla S, Mezzaroba N, Zorzet S. A new approach for the treatment of CLL using chlorambucil\/hydroxychloroquine-loaded anti-CD20 nanoparticles. Nano Research. 2016; 9:537-548.","DOI":"10.1007\/s12274-015-0935-3"},{"key":"49512","doi-asserted-by":"crossref","unstructured":"Colombo F, Durigutto P, De Maso L. Targeting CD34(+) cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis. J Autoimmun. 2019; 103(2019):102288-102301.","DOI":"10.1016\/j.jaut.2019.05.016"},{"key":"49513","doi-asserted-by":"crossref","unstructured":"Macor P, Secco E, Mezzaroba N. Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice. Leukemia. 2015; 29(2):406-414.","DOI":"10.1038\/leu.2014.185"},{"key":"49514","doi-asserted-by":"crossref","unstructured":"Mezzaroba N, Zorzet S, Secco E. New potential therapeutic approach for the treatment of B-cell malignancies using chlorambucil\/hydroxychloroquine-loaded anti-CD20 nanoparticles. PLoS One. 2013; 8(9):e74216.","DOI":"10.1371\/journal.pone.0074216"},{"key":"49515","doi-asserted-by":"crossref","unstructured":"Cavalli R, Argenziano M, Vigna E. Preparation and in vitro characterization of chitosan nanobubbles as theranostic agents. Colloids Surf B Biointerfaces. 2015; 129(1):39-46.","DOI":"10.1016\/j.colsurfb.2015.03.023"},{"key":"49516","doi-asserted-by":"crossref","unstructured":"Xing Z, Wang J, Ke H. The fabrication of novel nanobubble ultrasound contrast agent for potential tumor imaging. Nanotechnology. 2010; 21(14):145607-145615.","DOI":"10.1088\/0957-4484\/21\/14\/145607"},{"key":"49517","doi-asserted-by":"crossref","unstructured":"Argenziano M, Occhipinti S, Scomparin A. Exploring chitosan-shelled nanobubbles to improve HER2 + immunotherapy via dendritic cell targeting. Drug Deliv Transl Res. 2022; 12(8):2007-2018.","DOI":"10.1007\/s13346-022-01185-8"},{"key":"49518","doi-asserted-by":"crossref","unstructured":"Marano F, Frairia R, Rinella L. Combining doxorubicin-nanobubbles and shockwaves for anaplastic thyroid cancer treatment: preclinical study in a xenograft mouse model. Endocr Relat Cancer. 2017; 24(6):275-286.","DOI":"10.1530\/ERC-17-0045"},{"key":"49519","doi-asserted-by":"crossref","unstructured":"Shen S, Li Y, Xiao Y. Folate-conjugated nanobubbles selectively target and kill cancer cells via ultrasound-triggered intracellular explosion. Biomaterials. 2018; 181(1):293-306.","DOI":"10.1016\/j.biomaterials.2018.07.030"},{"key":"49520","doi-asserted-by":"crossref","unstructured":"Cavalli R, Bisazza A, Lembo D. Micro- and nanobubbles: a versatile non-viral platform for gene delivery. Int J Pharm. 2013; 456(2):437-445.","DOI":"10.1016\/j.ijpharm.2013.08.041"},{"key":"49521","unstructured":"Brown T. Design thinking. Harv Bus Rev. 2008; 86(6):84-92."},{"key":"49522","doi-asserted-by":"crossref","unstructured":"Cavalli R, Soster M, Argenziano M. Nanobubbles: a promising efficient tool for therapeutic delivery. Ther Deliv. 2016; 7(2):117-138.","DOI":"10.4155\/tde.15.92"},{"key":"49523","doi-asserted-by":"crossref","unstructured":"McCarthy JR, Patel P, Botnaru I, Haghayeghi P, Weissleder R, Jaffer FA. Multimodal nanoagents for the detection of intravascular thrombi. Bioconjug Chem. 2009; 20(6):1251-1255.","DOI":"10.1021\/bc9001163"},{"key":"49524","doi-asserted-by":"crossref","unstructured":"Marsh JN, Hu G, Scott MJ. A fibrin-specific thrombolytic nanomedicine approach to acute ischemic stroke. Nanomedicine (Lond). 2011; 6(4):605-615.","DOI":"10.2217\/nnm.11.21"},{"key":"49525","doi-asserted-by":"crossref","unstructured":"Alonso A, Dempfle CE, Della Martina A. In vivo clot lysis of human thrombus with intravenous abciximab immunobubbles and ultrasound. Thromb Res. 2009; 124(1):70-74.","DOI":"10.1016\/j.thromres.2008.11.019"},{"key":"49526","doi-asserted-by":"crossref","unstructured":"Wang X, Palasubramaniam J, Gkanatsas Y. Towards effective and safe thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets. Circ Res. 2014; 114(7):1083-1093.","DOI":"10.1161\/CIRCRESAHA.114.302514"},{"key":"49527","doi-asserted-by":"crossref","unstructured":"Hua X, Zhou L, Liu P. In vivo thrombolysis with targeted microbubbles loading tissue plasminogen activator in a rabbit femoral artery thrombus model. J Thromb Thrombolysis. 2014; 38(1):57-64.","DOI":"10.1007\/s11239-014-1071-8"},{"key":"49528","doi-asserted-by":"crossref","unstructured":"Del Papa N, Sheng YH, Raschi E. Human beta 2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-beta 2-glycoprotein I antibodies. J Immunol. 1998; 160(11):5572-5578.","DOI":"10.4049\/jimmunol.160.11.5572"},{"key":"49529","doi-asserted-by":"crossref","unstructured":"Lonati PA, Scavone M, Gerosa M. Blood cell-bound C4d as a marker of complement activation in patients with the antiphospholipid Syndrome. Front Immunol. 2019; 10(1):773-781.","DOI":"10.3389\/fimmu.2019.00773"},{"key":"49530","doi-asserted-by":"crossref","unstructured":"Shantsila E, Lip GY. The role of monocytes in thrombotic disorders. Insights from tissue factor, monocyte-platelet aggregates and novel mechanisms. Thromb Haemost. 2009; 102(5):916-924.","DOI":"10.1160\/TH09-01-0023"},{"key":"49531","doi-asserted-by":"crossref","unstructured":"McCarthy JR, Sazonova IY, Erdem SS. Multifunctional nanoagent for thrombus-targeted fibrinolytic therapy. Nanomedicine (Lond). 2012; 7(7):1017-1028.","DOI":"10.2217\/nnm.11.179"},{"key":"49532","doi-asserted-by":"crossref","unstructured":"Schwarz M, Meade G, Stoll P. Conformation-specific blockade of the integrin GPIIb\/IIIa: a novel antiplatelet strategy that selectively targets activated platelets. Circ Res. 2006; 99(1):25-33.","DOI":"10.1161\/01.RES.0000232317.84122.0c"},{"key":"49533","doi-asserted-by":"crossref","unstructured":"Wang X, Gkanatsas Y, Palasubramaniam J. Thrombus-targeted theranostic microbubbles: a new technology towards concurrent rapid ultrasound diagnosis and bleeding-free fibrinolytic treatment of thrombosis. Theranostics. 2016; 6(5):726-738.","DOI":"10.7150\/thno.14514"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281505\/74889","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281505\/75764","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10809\/74889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:02:24Z","timestamp":1794045744000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.281505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":47,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.281505","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,29]]}}}